{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:42:25Z","timestamp":1773960145011,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,23]]},"DOI":"10.7759\/cureus.56796","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T04:34:36Z","timestamp":1711254876000},"source":"Crossref","is-referenced-by-count":2,"title":["Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Raina","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Daigavane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Diabetic macular edema. (2022). Accessed. March 8, 2024: https:\/\/www.gene.com\/patients\/disease-education\/diabetic-macular-edema."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1106706","article-title":"Optimizing treatment for diabetic macular edema during cataract surgery","volume":"14","author":"Chan LK","year":"2023","unstructured":"Chan LK, Lin SS, Chan F, Ng DS. Optimizing treatment for diabetic macular edema during cataract surgery. Front Endocrinol (Lausanne). 2023, 14:1106706. 10.3389\/fendo.2023.1106706","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/24741264211028441","article-title":"Intravitreal injection therapy: current techniques and supplemental services","volume":"5","author":"Lam LA","year":"2021","unstructured":"Lam LA, Mehta S, Lad EM, Emerson GG, Jumper JM, Awh CC. Intravitreal injection therapy: current techniques and supplemental services. J Vitreoretin Dis. 2021, 5:438-47. 10.1177\/24741264211028441","journal-title":"J Vitreoretin Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim HM","year":"2021","unstructured":"Kim HM, Woo SJ. Ocular drug delivery to the retina: current innovations and future perspectives. Pharmaceutics. 2021, 13:108. 10.3390\/pharmaceutics13010108","journal-title":"Pharmaceutics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315590319","article-title":"Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema","volume":"6","author":"Mehta H","year":"2015","unstructured":"Mehta H, Gillies M, Fraser-Bell S. Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. Ther Adv Chronic Dis. 2015, 6:234-45. 10.1177\/2040622315590319","journal-title":"Ther Adv Chronic Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration","volume":"15","author":"Hussain RM","year":"2021","unstructured":"Hussain RM, Shaukat BA, Ciulla LM, Berrocal AM, Sridhar J. Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2021, 15:2653-65. 10.2147\/DDDT.S295223","journal-title":"Drug Des Devel Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01922","article-title":"Diabetic microvascular disease: an endocrine society scientific statement","volume":"102","author":"Barrett EJ","year":"2017","unstructured":"Barrett EJ, Liu Z, Khamaisi M, et al.. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab. 2017, 102:4343-410. 10.1210\/jc.2017-01922","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080008","article-title":"Diabetes-related microvascular and macrovascular diseases in the physical therapy setting","volume":"88","author":"Cade WT","year":"2008","unstructured":"Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008, 88:1322-35. 10.2522\/ptj.20080008","journal-title":"Phys Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.10-5-505","article-title":"Microvascular complications: pathophysiology and management","volume":"10","author":"Vithian K","year":"2010","unstructured":"Vithian K, Hurel S. Microvascular complications: pathophysiology and management. Clin Med (Lond). 2010, 10:505-9. 10.7861\/clinmedicine.10-5-505","journal-title":"Clin Med (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.26.2.77","article-title":"Microvascular and macrovascular complications of diabetes","volume":"26","author":"Fowler MJ","year":"2008","unstructured":"Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes . 2008, 26:77-82. 10.2337\/diaclin.26.2.77","journal-title":"Clin Diabetes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/19322968231194041","article-title":"Screening of diabetic retinopathy using artificial intelligence and tele-ophthalmology","volume":"17","author":"Kuklinski EJ","year":"2023","unstructured":"Kuklinski EJ, Henry RK, Shah M, Zarbin MA, Szirth B, Bhagat N. Screening of diabetic retinopathy using artificial intelligence and tele-ophthalmology. J Diabetes Sci Technol. 2023, 17:1724-5. 10.1177\/19322968231194041","journal-title":"J Diabetes Sci Technol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073427","article-title":"Involvement of cytokines in the pathogenesis of diabetic macular edema","volume":"22","author":"Noma H","year":"2021","unstructured":"Noma H, Yasuda K, Shimura M. Involvement of cytokines in the pathogenesis of diabetic macular edema. Int J Mol Sci. 2021, 22:3427. 10.3390\/ijms22073427","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(15)30404-4","article-title":"Vascular endothelial growth factor (VEGF) pathway","volume":"1","author":"Nilsson M","year":"2006","unstructured":"Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol. 2006, 1:768-70. 10.1016\/S1556-0864(15)30404-4","journal-title":"J Thorac Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119006","article-title":"Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth","volume":"98","author":"Xia P","year":"1996","unstructured":"Xia P, Aiello LP, Ishii H, et al.. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996, 98:2018-26. 10.1172\/JCI119006","journal-title":"J Clin Invest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya M","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011, 2:1097-105. 10.1177\/1947601911423031","journal-title":"Genes Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010275","article-title":"VEGF signaling in neurological disorders","volume":"19","author":"Shim JW","year":"2018","unstructured":"Shim JW, Madsen JR. VEGF signaling in neurological disorders. Int J Mol Sci. 2018, 19:275. 10.3390\/ijms19010275","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000315155","article-title":"Pathophysiology of macular edema","volume":"224 Suppl 1","author":"Scholl S","year":"2010","unstructured":"Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmologica. 2010, 224 Suppl 1:8-15. 10.1159\/000315155","journal-title":"Ophthalmologica"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128811","article-title":"Mechanisms of macular edema","volume":"10","author":"Haydinger CD","year":"2023","unstructured":"Haydinger CD, Ferreira LB, Williams KA, Smith JR. Mechanisms of macular edema. Front Med (Lausanne). 2023, 10:1128811. 10.3389\/fmed.2023.1128811","journal-title":"Front Med (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang J","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, Qiu Q.  Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022, 11:3362. 10.3390\/cells11213362","journal-title":"Cells"},{"key":"ref20","unstructured":"Ozurdex- Mechanism of action. (2024). Accessed. March 7, 2024: https:\/\/hcp.ozurdex.com\/mechanism-of-action."},{"key":"ref21","article-title":"Sustained release intraocular drug delivery devices for treatment of uveitis","volume":"6","author":"Haghjou N","year":"2011","unstructured":"Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011, 6:317-29.","journal-title":"J Ophthalmic Vis Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin JE","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011, 52:80-6. 10.1167\/iovs.10-5285","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6387","article-title":"Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes","volume":"52","author":"Chang-Lin JE","year":"2011","unstructured":"Chang-Lin JE, Burke JA, Peng Q, et al.. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011, 52:4605-9. 10.1167\/iovs.10-6387","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref24","unstructured":"Ozurdex - Clinical efficacy in DME. (2023). Accessed. March 7, 2024: https:\/\/hcp.ozurdex.com\/clinical-efficacy."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34673-z","article-title":"Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis","volume":"13","author":"Chi SC","year":"2023","unstructured":"Chi SC, Kang YN, Huang YM. Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: a systematic review and meta-analysis. Sci Rep. 2023, 13:7428. 10.1038\/s41598-023-34673-z","journal-title":"Sci Rep"},{"key":"ref26","unstructured":"Dexamethasone ophthalmic implant (ozurdex) and insert (dextenza). (2023). Accessed. March 7, 2024: https:\/\/www.aetna.com\/cpb\/medical\/data\/700_799\/0795.html."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13702","article-title":"Local delivery of corticosteroids in clinical ophthalmology: a review","volume":"48","author":"Fung AT","year":"2020","unstructured":"Fung AT, Tran T, Lim LL, et al.. Local delivery of corticosteroids in clinical ophthalmology: a review. Clin Exp Ophthalmol. 2020, 48:366-401. 10.1111\/ceo.13702","journal-title":"Clin Exp Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2023.101939","article-title":"Reflux hyphema from transient hypotony after Ozurdex\u00ae in eyes with prior GATT","volume":"32","author":"Tanenbaum RE","year":"2023","unstructured":"Tanenbaum RE, Xiao J, Qiu M. Reflux hyphema from transient hypotony after Ozurdex\u00ae in eyes with prior GATT. Am J Ophthalmol Case Rep. 2023, 32:101939. 10.1016\/j.ajoc.2023.101939","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_382_19","article-title":"Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: a systematic review and meta-analysis of randomized controlled trials","volume":"67","author":"Hu Q","year":"2019","unstructured":"Hu Q, Li H, Xu W, Du Y, Ma C, He J. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: a systematic review and meta-analysis of randomized controlled trials. Indian J Ophthalmol. 2019, 67:1800-9. 10.4103\/ijo.IJO_382_19","journal-title":"Indian J Ophthalmol"},{"key":"ref30","unstructured":"Ozurdex Prices, Coupons and Patient Assistance Programs. (2023). Accessed. March 7, 2024: https:\/\/www.drugs.com\/price-guide\/ozurdex."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-022-00401-z","article-title":"Cost-effectiveness of dexamethasone compared with aflibercept in na\u00efve diabetic macular edema","volume":"20","author":"Montes Rodr\u00edguez P","year":"2022","unstructured":"Montes Rodr\u00edguez P, Mateo Gab\u00e1s J, Esteban Flor\u00eda O, Honrubia Grijalbo A, Ascaso Puyuelo FJ. Cost-effectiveness of dexamethasone compared with aflibercept in na\u00efve diabetic macular edema. Cost Eff Resour Alloc. 2022, 20:61. 10.1186\/s12962-022-00401-z","journal-title":"Cost Eff Resour Alloc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20085462","article-title":"Cost-effectiveness of dexamethasone intravitreal implant in na\u00efve and previously treated patients with diabetic macular edema","volume":"20","author":"Medina-Baena M","year":"2023","unstructured":"Medina-Baena M, Cejudo-Corbal\u00e1n O, Labella-Quesada F, Girela-L\u00f3pez E. Cost-effectiveness of dexamethasone intravitreal implant in na\u00efve and previously treated patients with diabetic macular edema. Int J Environ Res Public Health. 2023, 20:5462. 10.3390\/ijerph20085462","journal-title":"Int J Environ Res Public Health"},{"key":"ref33","article-title":"For the treatment of adult patients with diabetic macular edema who are pseudophakic [Internet]","author":"Pharmacoeconomic Review Report: Dexamethasone (Ozurdex)","year":"2023","unstructured":"Pharmacoeconomic Review Report. Dexamethasone (Ozurdex): For the treatment of adult patients with diabetic macular edema who are pseudophakic [Internet]. Allergan Inc. (ed): Canadian Agency for Drugs and Technologies in Health, Ottawa, ON; 2023."},{"key":"ref34","unstructured":"Bevacizumab. (2024). Accessed. March 8, 2024: https:\/\/go.drugbank.com\/drugs\/DB00112."},{"key":"ref35","unstructured":"Avastin (bevacizumab). (2023). Accessed. March 8, 2024: https:\/\/www.avastin.com\/hcp\/mcrc\/proposed-moa.html."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S19555","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits","volume":"5","author":"Sinapis CI","year":"2011","unstructured":"Sinapis CI, Routsias JG, Sinapis AI, et al.. Pharmacokinetics of intravitreal bevacizumab (Avastin\u00ae) in rabbits. Clin Ophthalmol. 2011, 5:697-704. 10.2147\/OPTH.S19555","journal-title":"Clin Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri SJ","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007, 114:855-9. 10.1016\/j.ophtha.2007.01.017","journal-title":"Ophthalmology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner HA","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011, 364:603-15. 10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102582","article-title":"Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone I stage 3+ and aggressive posterior retinopathy of prematurity","volume":"2015","author":"Nicoar\u0103 SD","year":"2015","unstructured":"Nicoar\u0103 SD, Nascutzy C, Cristian C, Irimescu I, \u0218tef\u0103nu\u021b AC, Zaharie G, Drugan T. Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone I stage 3+ and aggressive posterior retinopathy of prematurity. J Ophthalmol. 2015, 2015:102582. 10.1155\/2015\/102582","journal-title":"J Ophthalmol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.3305","article-title":"Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial","volume":"137","author":"Hykin P","year":"2019","unstructured":"Hykin P, Prevost AT, Vasconcelos JC, et al.. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol. 2019, 137:1256-64. 10.1001\/jamaophthalmol.2019.3305","journal-title":"JAMA Ophthalmol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott IU","year":"2007","unstructured":"Scott IU, Edwards AR, Beck RW, et al.. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007, 114:1860-7. 10.1016\/j.ophtha.2007.05.062","journal-title":"Ophthalmology"},{"key":"ref42","unstructured":"Avastin (bevacizumab) important safety information. (2023). Accessed. March 8, 2024: https:\/\/www.avastin.com\/hcp\/safety.html."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_992_16","article-title":"Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario","volume":"65","author":"Jain P","year":"2017","unstructured":"Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol. 2017, 65:596-602. 10.4103\/ijo.IJO_992_16","journal-title":"Indian J Ophthalmol"},{"key":"ref44","unstructured":"Bevacizumab (Avastin). (2023). Accessed. January 11, 2024: https:\/\/eyewiki.aao.org\/Bevacizumab."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005244","article-title":"The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review","volume":"4","author":"Poku E","year":"2014","unstructured":"Poku E, Rathbone J, Wong R, Everson-Hock E, Essat M, Pandor A, Wailoo A. The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open. 2014, 4:e005244. 10.1136\/bmjopen-2014-005244","journal-title":"BMJ Open"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005094","article-title":"Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial","volume":"4","author":"Dakin HA","year":"2014","unstructured":"Dakin HA, Wordsworth S, Rogers CA, et al.. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open. 2014, 4:e005094. 10.1136\/bmjopen-2014-005094","journal-title":"BMJ Open"},{"key":"ref47","unstructured":"Expensive drugs. (2017). Accessed. March 8, 2024: https:\/\/www.aao.org\/eyenet\/article\/expensive-drugs."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7562-y","article-title":"Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases","volume":"19","author":"Sodr\u00e9 SL","year":"2019","unstructured":"Sodr\u00e9 SL, Barbosa IA, Pacheco IE, et al.. Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases. BMC Public Health. 2019, 19:1252. 10.1186\/s12889-019-7562-y","journal-title":"BMC Public Health"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37880","article-title":"Factors associated with a patient\u2019s decision to select a cost-effective vs the most effective therapy for their own eye disease","volume":"4","author":"Malik D","year":"2021","unstructured":"Malik D, Cao X, Sanchez JC, Gao T, Qian J, Montaner S, Sodhi A. Factors associated with a patient\u2019s decision to select a cost-effective vs the most effective therapy for their own eye disease. JAMA Netw Open. 2021, 4:e2037880. 10.1001\/jamanetworkopen.2020.37880","journal-title":"JAMA Netw Open"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119591","article-title":"Current treatments for diabetic macular edema","volume":"24","author":"Tatsumi T","year":"2023","unstructured":"Tatsumi T. Current treatments for diabetic macular edema. Int J Mol Sci. 2023, 24:9591. 10.3390\/ijms24119591","journal-title":"Int J Mol Sci"},{"key":"ref51","unstructured":"Diabetic macular edema. diagnosis and management. (2021). Accessed: March 8, 2024: https:\/\/www.aao.org\/eyenet\/article\/diabetic-macular-edema-diagnosis-and-management."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i8.1220","article-title":"Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema","volume":"12","author":"Karti O","year":"2021","unstructured":"Karti O, Saatci AO. Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes. 2021, 12:1220-32. 10.4239\/wjd.v12.i8.1220","journal-title":"World J Diabetes"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.129","article-title":"Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections","volume":"28","author":"Moisseiev E","year":"2014","unstructured":"Moisseiev E, Regenbogen M, Rabinovitch T, Barak A, Loewenstein A, Goldstein M. Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond). 2014, 28:980-5. 10.1038\/eye.2014.129","journal-title":"Eye (Lond)"},{"key":"ref54","article-title":"Bevordex - A multicentre randomised clinical trial of intravitreal bevacizumab (Avastin) versus intravitreal dexamethasone (OzurdexTM) for persistent diabetic macular oedema","volume":"55","author":"Gillies M","year":"2015","unstructured":"Gillies M. Bevordex - A multicentre randomised clinical trial of intravitreal bevacizumab (Avastin) versus intravitreal dexamethasone (OzurdexTM) for persistent diabetic macular oedema. Investigative opthalmology & visual science. 2015, 55:5053.","journal-title":"Investigative opthalmology & visual science"},{"key":"ref55","unstructured":"Diabetic macular edema treatment. what\u2019s the future. (2023). Accessed: January 11, 2024: https:\/\/diatribe.org\/future-diabetic-macular-edema-treatment-less-frequent-injections-and-noninvasive-options-are-hor...."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1159\/000516614","article-title":"New insights in resistant diabetic macular edema","volume":"244","author":"Kuroiwa DA","year":"2021","unstructured":"Kuroiwa DA, Malerbi FK, Regatieri CV. New insights in resistant diabetic macular edema. Ophthalmologica. 2021, 244:485-94. 10.1159\/000516614","journal-title":"Ophthalmologica"},{"key":"ref57","unstructured":"DR\/DME. Ongoing clinical trials and new diagnostic tools. (2023). Accessed: March 8, 2024: https:\/\/www.modernretina.com\/view\/dr-dme-ongoing-clinical-trials-and-new-diagnostic-tools."},{"key":"ref58","unstructured":"AAO 2023. New modes of treatments and new directions for diabetic macular edema. (2022). Accessed: January 11, 2024: https:\/\/www.medscape.com\/viewarticle\/996672."},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2017529","article-title":"Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies","volume":"7","author":"Miller K","year":"2018","unstructured":"Miller K, Fortun JA. Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac J Ophthalmol (Phila). 2018, 7:28-35. 10.22608\/APO.2017529","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref60","unstructured":"The latest research into novel therapies for diabetic macular edema. (2024). Accessed. March 8, 2024: https:\/\/retinalphysician.com\/issues\/2022\/september\/the-latest-research-into-novel-therapies-for-diabetic-macular-edema\/."},{"key":"ref61","unstructured":"EyePoint begins phase II diabetic macular oedema treatment trial. (2024). Accessed. March 8,2024: https:\/\/www.clinicaltrialsarena.com\/news\/eyepoint-macular-oedema-treatment-trial\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239514-intravitreal-ozurdex-vs-intravitreal-bevacizumab-for-diabetic-macular-edema-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T04:34:49Z","timestamp":1711254889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239514-intravitreal-ozurdex-vs-intravitreal-bevacizumab-for-diabetic-macular-edema-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.56796","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,23]]}}}